Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables: 2021-2025

Historic Receivables for Tg Therapeutics (TGTX) over the last 4 years, with Sep 2025 value amounting to $265.4 million.

  • Tg Therapeutics' Receivables rose 129.32% to $265.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $839.7 million, marking a year-over-year increase of 156.16%. This contributed to the annual value of $152.7 million for FY2024, which is 167.90% up from last year.
  • Tg Therapeutics' Receivables amounted to $265.4 million in Q3 2025, which was up 14.63% from $231.5 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Receivables peaked at $265.4 million during Q3 2025, and registered a low of $88,000 during Q2 2022.
  • Moreover, its 3-year median value for Receivables was $83.6 million (2024), whereas its average is $112.7 million.
  • In the last 5 years, Tg Therapeutics' Receivables crashed by 90.55% in 2022 and then skyrocketed by 19,768.18% in 2023.
  • Over the past 5 years, Tg Therapeutics' Receivables (Quarterly) stood at $1.4 million in 2021, then slumped by 90.55% to $88,000 in 2022, then surged by 19,768.18% to $57.0 million in 2023, then surged by 167.90% to $152.7 million in 2024, then soared by 129.32% to $265.4 million in 2025.
  • Its Receivables stands at $265.4 million for Q3 2025, versus $231.5 million for Q2 2025 and $190.1 million for Q1 2025.